Rodrigo Bezerra, Audes D M Feitosa, Vanildo S Guimarães-Neto, Romero Barbosa, Fábio F Moura, Marco A Mota-Gomes, Annelise M G Paiva, Weimar S Barroso, Roberto D Miranda, Eduardo C D Barbosa, Andréa A Brandão, Cibele I S Rodrigues, Luiz A Bortolotto, José L Lima-Filho, Andrei C Sposito, Wilson Nadruz
{"title":"通过单一疗法实现血压控制：来自办公室和家庭血压测量的真实证据。","authors":"Rodrigo Bezerra, Audes D M Feitosa, Vanildo S Guimarães-Neto, Romero Barbosa, Fábio F Moura, Marco A Mota-Gomes, Annelise M G Paiva, Weimar S Barroso, Roberto D Miranda, Eduardo C D Barbosa, Andréa A Brandão, Cibele I S Rodrigues, Luiz A Bortolotto, José L Lima-Filho, Andrei C Sposito, Wilson Nadruz","doi":"10.1097/HJH.0000000000004165","DOIUrl":null,"url":null,"abstract":"<p><p>Despite guidelines discouragement, antihypertensive monotherapy (AH-mono) remains widely used. This study assessed AH-mono prevalence and blood pressure control rates based on office and home measurements (OBP/HBPM) using contemporary targets (<130/80 mmHg). Three distinct cohorts undergoing OBP/HBPM assessments between July 2018 and July 2024 were analyzed: cohort 1 (n = 63 164) included treated patients with a single OBP/HBPM measurement; cohort 2 (n = 5676) comprised treated patients with two OBP/HBPM assessments at different time points; and cohort 3 (n = 974) involved individuals with OBP/HBPM measurements before and after initiating antihypertensive therapy. The prevalence of AH-mono was 42.7% in cohort 1, 36.6 and 32.4% in cohort 2, and 50.7% in cohort 3. Among those receiving AH-mono, OBP/HBPM control rates were 8.5% in cohort 1, 6.7 and 7.3% in Cohort 2, and 7.7% in cohort 3. These real-world findings highlight the persistent high prevalence of AH-mono despite its limited efficacy, with less than 10% of patients achieving blood pressure control.</p>","PeriodicalId":16043,"journal":{"name":"Journal of Hypertension","volume":" ","pages":""},"PeriodicalIF":4.1000,"publicationDate":"2025-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Achieving blood pressure control with monotherapy: real-world evidence from office and home blood pressure measurements.\",\"authors\":\"Rodrigo Bezerra, Audes D M Feitosa, Vanildo S Guimarães-Neto, Romero Barbosa, Fábio F Moura, Marco A Mota-Gomes, Annelise M G Paiva, Weimar S Barroso, Roberto D Miranda, Eduardo C D Barbosa, Andréa A Brandão, Cibele I S Rodrigues, Luiz A Bortolotto, José L Lima-Filho, Andrei C Sposito, Wilson Nadruz\",\"doi\":\"10.1097/HJH.0000000000004165\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Despite guidelines discouragement, antihypertensive monotherapy (AH-mono) remains widely used. This study assessed AH-mono prevalence and blood pressure control rates based on office and home measurements (OBP/HBPM) using contemporary targets (<130/80 mmHg). Three distinct cohorts undergoing OBP/HBPM assessments between July 2018 and July 2024 were analyzed: cohort 1 (n = 63 164) included treated patients with a single OBP/HBPM measurement; cohort 2 (n = 5676) comprised treated patients with two OBP/HBPM assessments at different time points; and cohort 3 (n = 974) involved individuals with OBP/HBPM measurements before and after initiating antihypertensive therapy. The prevalence of AH-mono was 42.7% in cohort 1, 36.6 and 32.4% in cohort 2, and 50.7% in cohort 3. Among those receiving AH-mono, OBP/HBPM control rates were 8.5% in cohort 1, 6.7 and 7.3% in Cohort 2, and 7.7% in cohort 3. These real-world findings highlight the persistent high prevalence of AH-mono despite its limited efficacy, with less than 10% of patients achieving blood pressure control.</p>\",\"PeriodicalId\":16043,\"journal\":{\"name\":\"Journal of Hypertension\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":4.1000,\"publicationDate\":\"2025-09-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Hypertension\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/HJH.0000000000004165\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PERIPHERAL VASCULAR DISEASE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hypertension","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/HJH.0000000000004165","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}
Achieving blood pressure control with monotherapy: real-world evidence from office and home blood pressure measurements.
Despite guidelines discouragement, antihypertensive monotherapy (AH-mono) remains widely used. This study assessed AH-mono prevalence and blood pressure control rates based on office and home measurements (OBP/HBPM) using contemporary targets (<130/80 mmHg). Three distinct cohorts undergoing OBP/HBPM assessments between July 2018 and July 2024 were analyzed: cohort 1 (n = 63 164) included treated patients with a single OBP/HBPM measurement; cohort 2 (n = 5676) comprised treated patients with two OBP/HBPM assessments at different time points; and cohort 3 (n = 974) involved individuals with OBP/HBPM measurements before and after initiating antihypertensive therapy. The prevalence of AH-mono was 42.7% in cohort 1, 36.6 and 32.4% in cohort 2, and 50.7% in cohort 3. Among those receiving AH-mono, OBP/HBPM control rates were 8.5% in cohort 1, 6.7 and 7.3% in Cohort 2, and 7.7% in cohort 3. These real-world findings highlight the persistent high prevalence of AH-mono despite its limited efficacy, with less than 10% of patients achieving blood pressure control.
期刊介绍：
The Journal of Hypertension publishes papers reporting original clinical and experimental research which are of a high standard and which contribute to the advancement of knowledge in the field of hypertension. The Journal publishes full papers, reviews or editorials (normally by invitation), and correspondence.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
